{"schema_version":"secwatch.filing_event.v1","accession":"0001534969-23-000121","form_type":"8-K","ticker":"SERA","cik":"0001534969","company_name":"SERA PROGNOSTICS, INC.","filed_at":"2023-12-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.415370+00:00","generated_at":"2026-06-07T17:03:55.104655+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Sera Prognostics PRIME study meets efficacy endpoint at interim; enrollment stopped","bullets":["DSMB recommended stopping PRIME study enrollment after one co-primary endpoint met efficacy stopping criteria at interim.","Company adopted DSMB recommendation; will stop enrollment to focus on analyzing and reporting available data.","CEO Zhenya Lindgardt described early stop as 'unexpected' and 'encouraging,' citing consistency with prior PREVENT and AVERT studies.","The PRIME trial is pivotal for the PreTRM® test, which aims to predict preterm birth risk."],"urls":{"canonical":"https://secwatch.observer/filing/0001534969-23-000121","json":"https://secwatch.observer/filing/0001534969-23-000121.json","markdown":"https://secwatch.observer/filing/0001534969-23-000121.md","text":"https://secwatch.observer/filing/0001534969-23-000121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534969/000153496923000121/0001534969-23-000121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534969/000153496923000121/sera-20231206.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T17:03:55.104655+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}